Metagenomi Q2 Revenue Turns Negative on Ionis Catch-Up; Cash Burn Accelerates
MGX is trading near its 52-week low of $1.13 (6.2% above the low).
Summary
Metagenomi's Q2 revenue turned negative after a $2.6 million Ionis catch-up adjustment, while cash reserves fell to $120.7M from $160.8M at year-end. The accelerated cash burn and collaboration headwinds heighten financing risk for the micro-cap gene-editing company.
Key Events · Earnings and Guidance · MGX
-
Revenue Turns Negative
Q2 collaboration revenue was -$0.3M vs $8.5M a year ago, due to a $2.6M cumulative catch-up adjustment from modifying the Ionis agreement. The adjustment reflects reduced economics from the partnership.
-
Cash Burn Accelerates
Cash, equivalents, and marketable securities fell to $120.7M from $160.8M at year-end 2025. Operating cash burn was $40.7M in H1 2026, up from $44.1M in H1 2025, but revenue headwinds make the burn more concerning.
-
Ionis Agreement Modified
On April 1, 2026, the Ionis collaboration was modified: the exploratory research plan was discontinued, and a new performance obligation was added for one Wave 1 target. The change triggered the $2.6M revenue reversal.
-
Real Estate Impairment
A sublease of office space in April 2026 triggered a $0.6M non-cash impairment on the right-of-use asset, indicating downsizing and potential cost-cutting.
Analysis · MGX · Life Sciences
A sharp reversal in collaboration revenue marked Metagenomi's second quarter, swinging to a negative $0.3 million from $8.5 million a year ago. The culprit was a $2.6 million cumulative catch-up adjustment triggered by changes to the Ionis partnership, which now carries reduced economics for a once-critical revenue stream. Meanwhile, cash, equivalents, and marketable securities dwindled to $120.7 million from $160.8 million at year-end, reflecting a $40.7 million operating cash burn in the first half. Although management asserts that cash is sufficient for at least 12 months, the accelerated burn rate and revenue headwinds raise near-term financing risk for this $46 million market cap biotech. A $0.6 million impairment on a sublease further signals real estate downsizing, while an ongoing securities class action adds legal overhang.
At the time of this filing, MGX was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.3M. The 52-week trading range was $1.13 to $3.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.